Oncolytics Biotech 提交 8-K，披露 GOBLET 研究 Cohort 4 更新数据公告
ONCOLYTICS BIOTECH INC (0001129928) (Filer)
Oncolytics Biotech 于 10 月 27 日提交 Form 8-K，称公司当天发布了 GOBLET 研究 Cohort 4 的更新数据。该队列评估 pelareorep 与 atezolizumab 用于二线及后线鳞状细胞肛门癌；相关信息随文件作为附件提供，不视为依据《证券交易法》第 18 条提交。
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________
FORM 8-K
___________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 27, 2026
___________________________________
Oncolytics Biotech Inc.
(Exact name of registrant as specified in its charter)
___________________________________
Nevada (State or other jurisdiction of incorporation) | 001-38512 (Commission File Number) | 98-0541667 (IRS Employer Identification No.) | |||||||||
4350 Executive Drive, Suite 325 San Diego, CA 92121 | 92121 | ||||||||||
(Address of principal executive offices) | (Zip Code) | ||||||||||
(403) 670-7377 | |||||||||||
(Registrant's telephone number, including area code) | |||||||||||
N/A | |||||||||||
(Former name or former address, if changed since last report) | |||||||||||
___________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | ||||
Securities registered pursuant to Section 12(b) of the Act: | ||||||||
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Common stock, par value $0.001 per share | ONCY | The Nasdaq Stock Market LLC | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Exchange Act (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On October 27, 2026, Oncolytics Biotech Inc. (the “Company”) issued a press release announcing updated data from Cohort 4 of the GOBLET study, which is evaluating pelareorep and atezolizumab in second-line and later squamous cell anal cancer. The information set forth in this Item 8.01 and in Exhibit 99.1 is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. | Description | |||||||
99.1 | Press Release issued by Oncolytics Biotech Inc., dated as of October27, 2026. | |||||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 27, 2026
ONCOLYTICS BIOTECH INC. | |||||
By: | /s/ Kirk Look | ||||
Name: | Kirk Look | ||||
Title: | Chief Financial Officer | ||||
来源：SEC EDGAR · 本站存档